Molecular pathways that drive diabetic kidney disease.

Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K. · 2023

Read Molecular pathways that drive diabetic kidney disease. by Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9927939.txt.

Introduction

Mohandes and co-authors map the molecular pathways that drive diabetic kidney disease. Kidney disease is a major cause of death in diabetes. Diabetic kidney disease accounts for close to half of all chronic kidney disease. It tends to arise when poor blood sugar control meets genetic risk.

The review centers on podocytes and endothelial cells in early disease. Proximal tubule changes track closely with filtration rate decline. High glucose strains kidney cells, alters their metabolism, and raises energy demand. Later, mitochondrial faults add oxidative stress and inflammation, driving scarring. Blocking the renin-angiotensin system or sodium-glucose transport slows decline. The authors point to new pathways as sources of needed drugs.

Catalog record

CREATORMohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9927939

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Molecular pathways that drive diabetic kidney disease By Samer Mohandes, Tomohito Doke, Hailong Hu, Dhanunjay Mukhi, Poonam Dhillon, Katalin Susztak Published in: The Journal of Clinical Investigation DOI: 10.1172/JCI165654 ABSTRACT Kidney disease is a major driver of mortality among patients with diabetes and diabetic kidney disease (DKD) is responsible for close to half of all chronic kidney disease cases. DKD usually develops in a genetically susceptible individual as a result of poor metabolic (glycemic) control. Molecular and genetic studies indicate the key role of podocytes and endothelial cells in driving albuminuria and early kidney disease in diabetes. Proximal tubule changes show a strong association with the glomerular filtration rate. Hyperglycemia represents a key cellular stress in the kidney by altering cellular metabolism in endothelial cells and podocytes and by imposing an excess workload requiring energy and oxygen for proximal tubule cells. Changes in metabolism induce early adaptive cellular hypertrophy and reorganization of the actin cytoskeleton. Later, mitochondrial defects contribute to increased oxidative stress and activation of inflammatory pathways, causing progressive kidney function decline and fibrosis. Blockade of the renin-angiotensin system or the sodium-glucose cotransporter is associated with cellular protection and slowing kidney function decline. Newly identified molecular pathways could provide the basis for the development of much-needed novel therapeutics. INTRODUCTION Diabetic kidney disease (DKD) refers to the clinical diagnosis of kidney disease attributed to diabetes based on the presence of albuminuria (>300 mg/d) and/or low estimated glomerular filtration rate (eGFR) (<60 cc/min) in patients with type 2 diabetes, but an even lower threshold of albuminuria can signify DKD in patients with type 1 diabetes. Diabetic nephropathy refers to the histological changes attributed to diabetes that are observed on kidney biopsies of patients with diabetes, including diffuse thickening of the glomerular basement membrane (GBM), mesangial expansion, and nodular sclerosis (Kimmelstiel-Wilson nodules) (1). Albeit these terms are often used interchangeably, here we will use the broader term of DKD to encompass the kidney disease attributable to diabetes. Epidemiological studies indicate that around 40% of patients with diabetes develop DKD (2). However, this number varies depending on the DKD diagnostic criteria used (3). Overall, DKD remains the leading cause of end-stage kidney disease in the Western hemisphere, representing an enormous economic burden. Patients with DKD have increased cardiovascular disease risk and mortality. While the incidence of cardiovascular disease has markedly declined over the last three decades, the incidence of DKD has not declined similarly (4). Our understanding of DKD remains incomplete, in part because animal models poorly recapitulate human DKD (5). The clinical disease manifestation appears to be heterogeneous; for instance, many patients progress in the absence of a large amount of albuminuria, and the histological characterization of these patients is still incomplete (6). DKD progression is variable, and no available biomarkers can accurately predict kidney function decline (7). In the last 3 to 5 years there have been some promising results in multiple clinical trials of drugs for treatment of DKD; while these drugs slow disease progression, they do not stop kidney function decline. Improved mechanistic understanding of DKD pathophysiology will be essential for new drug development. Below, we will review the current evidence implicating genetic, epigenetic, and metabolic alterations in DKD, linking these changes to microvascular, tubule, and podocyte dysfunction in disease progression. DKD HAS A STRONG HERITABLE COMPONENT The genetic basis of DKD was first suggested by observation of the familial disease aggregation (8). Family-based early linkage studies identified suggestive genes and variants that were not replicated in later unbiased genome-wide association studies (GWAS). The Genetics of Nephropathy International Effort (GENIE) consortium (9), with a sample size of 6,000 subjects, identified two novel signals near the AFF3 and the RGMA/MCTP2 gene regions. The Surrogate Markers for Micro- and Macrovascular Hard Endpoints for Innovative Diabetes Tools (SUMMIT) Consortium (10), with a sample size of 12,000, only observed suggestive signals near AFF3, CNTNAP2, NRG3, PTPN13, and GABRR1 genes (11). Increasing the sample size to 20,000 subjects with type 1 diabetes helped to identify a strong signal in the COL4A3 gene that was associated with a thinner GBM and protection from albuminuria and DKD. Two other variants associated with cell adhesion were identified near the COLEC11 and DDR1 genes (12). The CKDGen, UKBB, and MVP consortia have performed extensive large eGFR GWAS studies with over 1 million subjects and identified more than 800 loci for eGFR (13). A subanalysis of subjects with diabetes (mostly type 2 diabetes) could not identify major differences in the genetic architecture of eGFR in subjects with or without diabetes (14). In summary, the genetic architecture of albuminuria in DKD appears to be different from that of eGFR. The genetic architecture of eGFR is very similar in those with and without diabetes. The proteinuria phenotype seems to cluster with genes expressed by podocytes. EPIGENETIC CHANGES ARE BOTH HERITABLE AND METABOLITE-SENSITIVE Patients with diabetes who experience a period of poor glycemic control have higher kidney disease incidence even after several decades of good metabolic control (15), a phenomenon dubbed “metabolic memory.” Epigenomic changes are proposed to be responsible for the metabolic memory. Epigenome-modifying enzymes use substrates from the intermediate metabolism, rendering them sensitive to intracellular metabolite fluctuation (16). Indeed, culturing cells in high glucose causes changes in DNA cytosine methylation and histone modification (17). However, the epigenome is cell type specific, and in vitro cultured cells are different from in vivo, representing an important challenge for epigenetic studies. Methylation changes in DKD. Methylation of DNA cytosines is an important epigenetic modification that can cause transcriptional repression. The importance of methylation in metabolic memory was suggested by the identification of methylation differences, for example in the TXNIP (thioredoxin-interacting protein) locus, in the Diabetes Complications Control Trial (DCCT) cohort (18). Mediation analysis indicated the causal role of TXNIP methylation and hyperglycemia in DKD progression (19). These methylation differences persisted in the follow-up EDIC cohort, suggesting their role in metabolic memory (20). In the Pima Indian cohort, methylation of 77 sites in blood samples was associated with GFR decline (21). In patients with diabetes among the Chronic Renal Insufficiency Cohort, an association between methylation changes and albuminuria, glycemic control, baseline eGFR, and eGFR decline was observed. The study also examined the relationship between genotype and methylation levels (methylation quantitative trait locus [meQTL]). Integration of GWAS and meQTL enabled identification of likely causal methylation changes for DKD development and novel risk genes (22). Very few methylation studies analyzed changes in human kidney tissue samples. Among these, the earliest study by Ko et al. used an isoschizomer-based DNA digestion method and identified methylation changes in enhancer regions in diseased kidneys (23). Later, Gluck et al. identified loci showing differential methylation between healthy and diseased kidneys. Furthermore, kidney cytosine methylation changes improved the prediction of GFR decline, supporting their role in DKD (24). Higher methylation levels in enhancer regions correlated with lower expression of tubule-specific genes, suggesting a role of DNA methylation in epithelial dedifferentiation (25). The degree of methylation of the TNFα gene correlated with eGFR decline and fibrosis. Epigenetic editing of the TNF locus (using dCas9-Tet1) confirmed the causal role of the methylation of this region in TNF expression and disease development (5). Mouse models with diabetes displayed higher DNA methyltransferase 1 (DNMT1) levels.

Read the complete text